Skip to main content
Home
Browse by Topic
Special Series
Conference Correspondent
NSCLC 2022 Midyear Review
Supplements
Special Issues
Multimedia
Video Library
Rapid Reactions
Home
Browse by Topic
Special Series
Conference Correspondent
NSCLC 2022 Midyear Review
Supplements
Special Issues
Multimedia
Video Library
Rapid Reactions
Subscribe
FDA Approvals, News & Updates
Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer
FDA Approvals, News & Updates
Read More ›
First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL
FDA Approvals, News & Updates
Read More ›
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
FDA Approvals, News & Updates
,
Breast Cancer
Read More ›
Ivosidenib Now FDA-Approved as First-Line Treatment for AML with IDH1 Mutation
FDA Approvals, News & Updates
Read More ›
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
FDA Approvals, News & Updates
Read More ›
April 16, 2019 – FDA Approvals, News & Updates
FDA Approvals, News & Updates
Read More ›
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Breast Cancer
,
FDA Approvals, News & Updates
Read More ›
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Breast Cancer
,
FDA Approvals, News & Updates
Read More ›
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Lung Cancer
,
FDA Approvals, News & Updates
Read More ›
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
FDA Approvals, News & Updates
Read More ›
Page 2 of 3
1
2
3